Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • GiddyGap@lemm.ee
    link
    fedilink
    arrow-up
    9
    ·
    1 year ago

    What a clown comment. Other countries with universal healthcare pay significantly less for care and pharmaceuticals than Americans because their governments handle the negotiations.